Literature DB >> 17114590

Vascular endothelial growth factor biology: clinical implications for ocular treatments.

R B Bhisitkul1.   

Abstract

Decades of research on vascular endothelial growth factor (VEGF) have reached fruition with the recent development of intravitreal anti-VEGF treatments for exudative age-related macular degeneration. VEGF is a critical regulator of angiogenesis and vascular permeability with diverse roles, both pathological and physiological, during development and adulthood. The aim of this article is to review aspects of VEGF biology that may be relevant to the clinical use of anti-VEGF agents in ophthalmology: molecular characteristics and isoforms of VEGF; its roles in vasculogenesis, vascular maintenance and angiogenesis; systemic effects of VEGF inhibition; and properties of current anti-VEGF agents.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17114590      PMCID: PMC1857529          DOI: 10.1136/bjo.2006.098426

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  72 in total

1.  A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema.

Authors:  Emmett T Cunningham; Anthony P Adamis; Michael Altaweel; Lloyd P Aiello; Neil M Bressler; Donald J D'Amico; Mauro Goldbaum; David R Guyer; Barrett Katz; Manju Patel; Steven D Schwartz
Journal:  Ophthalmology       Date:  2005-10       Impact factor: 12.079

2.  Sequential steps during vasculogenesis and angiogenesis in the very early human placenta.

Authors:  R Demir; U A Kayisli; S Cayli; B Huppertz
Journal:  Placenta       Date:  2005-07-18       Impact factor: 3.481

3.  Placenta growth factor and vascular endothelial growth factor B and C expression in microvascular endothelial cells and pericytes. Implication in autocrine and paracrine regulation of angiogenesis.

Authors:  H Yonekura; S Sakurai; X Liu; H Migita; H Wang; S Yamagishi; M Nomura; M J Abedin; H Unoki; Y Yamamoto; H Yamamoto
Journal:  J Biol Chem       Date:  1999-12-03       Impact factor: 5.157

4.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

Authors:  David M Brown; Peter K Kaiser; Mark Michels; Gisele Soubrane; Jeffrey S Heier; Robert Y Kim; Judy P Sy; Susan Schneider
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

5.  Ranibizumab for neovascular age-related macular degeneration.

Authors:  Philip J Rosenfeld; David M Brown; Jeffrey S Heier; David S Boyer; Peter K Kaiser; Carol Y Chung; Robert Y Kim
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

6.  Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling.

Authors:  Fabienne Baffert; Tom Le; Barbara Sennino; Gavin Thurston; Calvin J Kuo; Dana Hu-Lowe; Donald M McDonald
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-09-19       Impact factor: 4.733

7.  Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion.

Authors:  Hidetaka Noma; Atsushi Minamoto; Hideharu Funatsu; Hidetoshi Tsukamoto; Kensuke Nakano; Hidetoshi Yamashita; Hiromu K Mishima
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-08-13       Impact factor: 3.117

8.  The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide.

Authors:  A E Fung; P J Rosenfeld; E Reichel
Journal:  Br J Ophthalmol       Date:  2006-07-19       Impact factor: 4.638

9.  Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.

Authors:  Robert L Avery; Dante J Pieramici; Melvin D Rabena; Alessandro A Castellarin; Ma'an A Nasir; Matthew J Giust
Journal:  Ophthalmology       Date:  2006-02-03       Impact factor: 12.079

10.  A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165.

Authors:  Joon-Hwa Lee; Marella D Canny; Andrea De Erkenez; Dominik Krilleke; Yin-Shan Ng; David T Shima; Arthur Pardi; Fiona Jucker
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-15       Impact factor: 11.205

View more
  48 in total

1.  EXTEND III: efficacy and safety of ranibizumab in South Korean and Taiwanese patients with subfoveal CNV secondary to AMD.

Authors:  Oh-Woong Kwon; Fenq Lih Lee; Hum Chung; Chi-Chun Lai; Shwu-Jiuan Sheu; Young-Hee Yoon
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-03-02       Impact factor: 3.117

Review 2.  Aflibercept for intravitreal injection: in neovascular age-related macular degeneration.

Authors:  James E Frampton
Journal:  Drugs Aging       Date:  2012-10       Impact factor: 3.923

Review 3.  Therapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities.

Authors:  Chelsea C Estrada; Alejandro Maldonado; Sandeep K Mallipattu
Journal:  J Am Soc Nephrol       Date:  2019-01-14       Impact factor: 10.121

4.  Sema3A maintains corneal avascularity during development by inhibiting Vegf induced angioblast migration.

Authors:  Chelsey C McKenna; Ana F Ojeda; James Spurlin; Sam Kwiatkowski; Peter Y Lwigale
Journal:  Dev Biol       Date:  2014-05-06       Impact factor: 3.582

Review 5.  Ranibizumab: a review of its use in the treatment of neovascular age-related macular degeneration.

Authors:  James E Frampton
Journal:  Drugs Aging       Date:  2013-05       Impact factor: 3.923

6.  Non-arteritic ischemic optic neuropathy followed by intravitreal bevacizumab injection: is there an association?

Authors:  Ali A Bodla; Prasad Rao
Journal:  Indian J Ophthalmol       Date:  2010 Jul-Aug       Impact factor: 1.848

7.  Pegaptanib Sodium versus Pegaptanib Sodium Combined with Macular Laser Photocoagulation or Laser Alone for Diabetic Macular Edema.

Authors:  G Querques; A V Bux; A R Fusco; C Iaculli; N Delle Noci
Journal:  J Ophthalmol       Date:  2010-03-09       Impact factor: 1.909

8.  Role of pegaptanib sodium in the treatment of neovascular age-related macular degeneration.

Authors:  Sobha Sivaprasad
Journal:  Clin Ophthalmol       Date:  2008-06

9.  Induction of VEGFA mRNA translation by CoCl2 mediated by HuR.

Authors:  Cecilia Osera; Jennifer L Martindale; Marialaura Amadio; Jiyoung Kim; Xiaoling Yang; Christopher A Moad; Fred E Indig; Stefano Govoni; Kotb Abdelmohsen; Myriam Gorospe; Alessia Pascale
Journal:  RNA Biol       Date:  2015-09-01       Impact factor: 4.652

10.  Enhanced differentiation of retinal progenitor cells using microfabricated topographical cues.

Authors:  Mark R Steedman; Sarah L Tao; Henry Klassen; Tejal A Desai
Journal:  Biomed Microdevices       Date:  2010-06       Impact factor: 2.838

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.